Original Article
A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema
N Engl J Med 2003; 348:2059-2073May 22, 2003
- Abstract
Background
Lung-volume–reduction surgery has been proposed as a palliative treatment for severe emphysema. Effects on mortality, the magnitude and durability of benefits, and criteria for the selection of patients have not been established.
Methods
A total of 1218 patients with severe emphysema underwent pulmonary rehabilitation and were randomly assigned to undergo lung-volume–reduction surgery or to receive continued medical treatment.
Results
Overall mortality was 0.11 death per person-year in both treatment groups (risk ratio for death in the surgery group, 1.01; P=0.90). After 24 months, exercise capacity had improved by more than 10 W in 15 percent of the patients in the surgery group, as compared with 3 percent of patients in the medical-therapy group (P<0.001). With the exclusion of a subgroup of 140 patients at high risk for death from surgery according to an interim analysis, overall mortality in the surgery group was 0.09 death per person-year, as compared with 0.10 death per person-year in the medical-therapy group (risk ratio, 0.89; P=0.31); exercise capacity after 24 months had improved by more than 10 W in 16 percent of patients in the surgery group, as compared with 3 percent of patients in the medical-therapy group (P<0.001). Among patients with predominantly upper-lobe emphysema and low exercise capacity, mortality was lower in the surgery group than in the medical-therapy group (risk ratio for death, 0.47; P=0.005). Among patients with non–upper-lobe emphysema and high exercise capacity, mortality was higher in the surgery group than in the medical-therapy group (risk ratio, 2.06; P=0.02).
Conclusions
Overall, lung-volume–reduction surgery increases the chance of improved exercise capacity but does not confer a survival advantage over medical therapy. It does yield a survival advantage for patients with both predominantly upper-lobe emphysema and low base-line exercise capacity. Patients previously reported to be at high risk and those with non–upper-lobe emphysema and high base-line exercise capacity are poor candidates for lung-volume–reduction surgery, because of increased mortality and negligible functional gain.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Probability of Death as a Function of the Number of Months after Randomization.Figure 2
Histograms of Changes from Base Line in Exercise Capacity (Maximal Workload), Percentage of the Predicted Value for Forced Expiratory Volume in One Second (FEV1), and Quality of Life (Quality of Well-Being Score) after 6, 12, and 24 Months of Follow-up.Article Activity
- Article
Lung-volume–reduction surgery has been proposed as a palliative treatment for patients with severe emphysema.1-8 Uncertainty about morbidity and mortality; the occurrence, magnitude, and duration of benefit; and preoperative predictors of benefit led us to conduct a federally sponsored, multicenter, randomized clinical trial, the National Emphysema Treatment Trial (NETT).9 The primary outcomes for the trial were mortality and maximal exercise capacity two years after randomization. Secondary outcomes included the distance walked in six minutes, pulmonary function, quality of life, and degree of dyspnea. An important goal of the trial was to identify patient-selection criteria for lung-volume–reduction surgery. Criteria for inclusion were crafted to include all patients who might benefit from lung-volume–reduction surgery. Here, we report outcomes for all patients who underwent randomization and identify subgroups of patients with varying levels of risk and benefit.
Methods
The design and methods of the trial have been described previously.9 We summarize them below.
Population of Patients and Assessments
At 17 clinics, patients with severe emphysema underwent comprehensive medical evaluation to ensure compliance with usual medical therapy and to rule out clinically significant coexisting conditions.9 Base-line measurements were completed after pulmonary rehabilitation but before randomization, and patients underwent complete evaluations at 6 months, 12 months, and yearly thereafter. Overall mortality and maximal exercise capacity (on cycle ergometry with an increment of 5 or 10 W per minute after three minutes of pedaling with the ergometer set at 0 W and the patient breathing 30 percent oxygen) were the primary outcome measures. Secondary outcome measures included pulmonary function,10,11 the distance walked in six minutes,12,13 and the results on a self-administered questionnaire about health-related quality of life (St. George's Respiratory Questionnaire),14 a general quality-of-life questionnaire (the Quality of Well-Being scale),15 and a dyspnea questionnaire (the University of California, San Diego, Shortness of Breath Questionnaire16).
The distribution of emphysema was classified as heterogeneous or homogeneous on the basis of high-resolution computed tomography (CT) with the use of a visual scoring system.17 In addition, the radiologist classified the craniocaudal distribution of emphysema as predominantly affecting the upper lobes, predominantly affecting the lower lobes, diffuse, or predominantly affecting the superior segments of the lower lobes; the latter three categories were grouped together as predominantly non–upper-lobe emphysema for the purposes of our analysis. The ratio of perfusion in the upper regions of the lungs to that in the lower regions was quantified on the basis of radionuclide scans of the lungs that were interpreted at each center.
Before randomization, eligible patients completed 6 to 10 weeks of pulmonary rehabilitation supervised by study personnel. All patients provided written informed consent, and the study was approved by the institutional review board at each clinic. In May 2001, patients with a forced expiratory volume in one second (FEV1) that was 20 percent or less of the predicted value and either a homogeneous distribution of emphysema or a carbon monoxide diffusing capacity that was 20 percent or less of the predicted value were determined to be at high risk for death after lung-volume–reduction surgery, with a low probability of functional benefit,17 and were no longer eligible for randomization. Detailed criteria for inclusion in and exclusion from the trial are listed in Supplementary Appendix 1 (available with the full text of this article at http://www.nejm.org).
Patients randomly assigned to lung-volume–reduction surgery underwent bilateral stapled wedge resection through a median sternotomy or video-assisted thoracic surgery; the goal was to resect 20 to 35 percent of each lung, targeting the most diseased portions. Eight centers performed lung-volume reduction by median sternotomy alone, three centers by video-assisted thoracic surgery alone, and six by median sternotomy or video-assisted thoracic surgery selected randomly. Patients' adherence to medical regimens, abstinence from tobacco use, and pulmonary-rehabilitation treatment at home were monitored through regular telephone calls and clinic visits.
Definition of Outcomes
Vital status, ascertained as of December 2002, was determined by reports from the clinical centers and review of the Social Security Administration's December 2002 Death Master File.18,19 Total, 30-day, and 90-day mortality from all causes were measured from the day of randomization for both treatment groups. On the basis of previous experience, we defined improvement in maximal exercise capacity as an increase in the maximal workload of more than 10 W from the postrehabilitation base-line level. Improvement in health-related quality of life was defined as a decrease in the score on the St. George's Respiratory Questionnaire of more than 8 points (on a 100-point scale) from the base-line level (measured after rehabilitation). These thresholds are higher than those typically used to define minimal clinically important differences (e.g., a four-point change on the respiratory questionnaire is usually used20) but were selected to represent a degree of improvement that would be appropriate to justify the high risks associated with surgery in patients with severe emphysema. Patients who died or were missing data required for the assessment were considered not to have had improvement.
Statistical Analysis
All analyses were performed according to the intention-to-treat principle. Fisher's exact test was used to compare the proportions of patients in each group who died.21 The trial protocol specified that the primary comparison would be between the proportions of patients in the two groups who died rather than a comparison with the use of a typical rank-based test (e.g., a log-rank or Wilcoxon test) for differences in mortality, because the hazard functions for death were expected to cross, resulting in nonproportional hazards. This crossing of hazards was anticipated as a consequence of the expected perioperative mortality, potentially followed by lower mortality in the surgery group after six months.22 The risk ratio for death was estimated on the basis of the overall mortality in each group after a mean of 29.2 months of follow-up.21
Despite randomization, differential early mortality makes survivors in the surgery group appear healthier than their counterparts in the medical-therapy group. This imbalance confounds the interpretation of outcomes measured only in survivors, such as exercise capacity, pulmonary function, and quality of life. Therefore, we used classifications derived from measured outcomes defined for all patients, such as improvement versus no improvement, with the latter category also including patients who were unable to complete the evaluation or who had died. The cutoff point used for a derived variable — for example, the definition of improvement — is necessarily somewhat arbitrary.
Histograms were used to compare the surgery group and the medical-therapy group in terms of the distributions of categories of change from base line in the outcome measures; all patients who were followed for 6, 12, and 24 months were included in these analyses. The histograms included 8 or 10 categories of the change measured in survivors (scored from 2 to 12, with higher scores indicating more improvement), a category for patients who died (scored as 0), and a category for patients who missed or were unable to complete the evaluation (scored as 1). For cycle ergometry, patients who could pedal only with the ergometer set at 0 W were also given a score of 1. For the Quality of Well-Being scale, patients who died were assigned a score of 0 on the questionnaire for that visit, and patients who did not complete the questionnaire were assigned a score equal to half of the lowest score observed for that visit. P values for the comparisons of the two groups in terms of the distribution of scores were derived by the Wilcoxon rank-sum test.23
Subgroups of patients with differential risks or benefits were identified with the use of a series of logistic-regression analyses that included as the outcome death, improvement in exercise capacity, or improvement in health-related quality of life at 6, 12, or 24 months. For each outcome, the model included terms for the treatment-group assignment, a base-line prognostic factor, and the interaction between the treatment group and the prognostic factor, to test whether or not the factor was associated with differential outcome. P values for the interaction terms were determined by exact-score tests for logistic regression,24 and factors with statistically significant interactions were also examined in logistic models including pairwise combinations of the factors with corresponding interaction terms.
Most prognostic factors were identified by a hypothesis specified in the trial protocol (age, percentage of the predicted value for the FEV1, partial pressure of arterial carbon dioxide, percentage of the predicted value for the residual volume, distribution of perfusion on radionuclide scanning of the lungs, homogeneity or heterogeneity of the distribution of emphysema on CT, and presence or absence of hyperinflation on chest radiography).17 Other base-line prognostic factors were added by the data and safety monitoring board or the investigators after the initiation of the trial but well before the completion of data collection (percentage of predicted value for carbon monoxide diffusing capacity, maximal exercise capacity, ratio of residual volume to total lung capacity, ratio of expired ventilation in one minute to carbon dioxide excretion in one minute, presence or absence of upper-lobe predominance of emphysema, degree of dyspnea, quality of life, race or ethnic group, and sex). Measured prognostic factors were categorized into approximate quartiles, and patients in the quartile with the worst prognosis were compared with all other patients. The prognostic factors were analyzed quarterly as part of ongoing monitoring of the study to meet the a priori objective of identifying characteristics of patients who might have a differential risk of harm or differential benefit from lung-volume–reduction surgery.
A base-line maximal exercise capacity in the lowest quartile (≤25 W) was one of the two prognostic factors that identified patients with a differential risk of death. Recognizing that there are differences between men and women in exercise capacity, we refined the cutoff point for base-line maximal exercise capacity by examining a range of sex-specific cutoff points, and we found that the sex-specific 40th percentile (25 W for women and 40 W for men) was the best cutoff point for the classification of patients with a differential risk of death from lung-volume–reduction surgery (see Supplementary Appendix 2, available with the full text of this article at http://www.nejm.org).
All reported P values are based on two-sided tests. P values were not corrected for multiple comparisons. The primary and secondary objectives of the trial were identified by hypothesis before the study began and specifically included the identification of subgroups associated with differential harm or benefit from lung-volume–reduction surgery. Although a large number of statistical tests were possible, we limited the number through planning and an orderly analysis of the data. The prognostic factors identified have a plausible clinical rationale and were associated with large, statistically significant risk ratios.
The study protocol specified that recruitment would end by July 2002, with an accrual of 2500 patients and study completion in December 2002. This design was based on a primary survival comparison allowing for 8 percent mortality in the group assigned to medical therapy and for a rate of unplanned crossover of 30 percent among those assigned to medical therapy.9 The trial was ended on the planned date despite accrual that was lower than expected. Had the study been designed with the assumptions of the higher mortality rate and the lower crossover rate that were actually observed (0.11 death per person-year and 5.4 percent, respectively), the recruitment goal would have been 1190 patients.
Results
Study Patients
Between January 1998 and July 2002, 3777 patients were evaluated, and 1218 patients underwent randomization — 608 to surgery and 610 to medical therapy. The groups had similar base-line characteristics after rehabilitation, except that there was a higher proportion of men in the medical-therapy group (Table 1Table 1
Characteristics of All 1218 Patients at Base Line.) (Results for subgroups are given in Supplementary Appendix 3 [available with the full text of this article at http://www.nejm.org]). As of December 2002, 99 percent of surviving patients continued to complete quarterly telephone interviews or annual clinic visits.Treatment
Of the 608 patients assigned to lung-volume–reduction surgery, 580 (95.4 percent) underwent surgery (406 [70.0 percent] of them by median sternotomy and 174 [30.0 percent] by video-assisted thoracic surgery), 21 (3.5 percent) declined to undergo surgery, and 7 (1.2 percent) were deemed to be unsuitable for surgery after randomization. The median time from randomization to surgery was 10 days; 74 of the patients assigned to lung-volume–reduction surgery (12.2 percent) underwent surgery more than 14 days after randomization. Deviations from the surgical protocol (unilateral surgery or bilateral surgery performed in two sessions) occurred in 12 patients (2.0 percent) because of intraoperative factors; 4 patients in the surgery group (0.7 percent) received lung transplants after undergoing lung-volume–reduction surgery. Among the 610 patients assigned to medical therapy, 33 (5.4 percent) underwent lung-volume–reduction surgery outside the study, and 15 (2.5 percent) received lung transplants during follow-up.
Outcomes for All 1218 Patients
The 90-day mortality rate in the surgery group was 7.9 percent (95 percent confidence interval, 5.9 to 10.3) and was significantly higher than that in the medical-therapy group (1.3 percent [95 percent confidence interval, 0.6 to 2.6], P<0.001) (Table 2Table 2
Mortality among All Patients and in Subgroups.). The 90-day mortality rate was similar among patients who underwent video-assisted thoracic surgery and among those who underwent median sternotomy (6.1 percent and 8.6 percent, respectively; P=0.33). All clinics reported similar rates of mortality, morbidity, and common intraoperative and postoperative complications. During follow-up (mean duration, 29.2 months), 157 patients assigned to lung-volume–reduction surgery and 160 assigned to medical therapy died. The total mortality rate was 0.11 death per person-year in both groups (risk ratio for death in the surgery group, 1.01; P=0.90) (Table 2). There was no significant difference in overall mortality despite a higher early mortality rate in the surgery group (Figure 1AFigure 1Kaplan–Meier Estimates of the Probability of Death as a Function of the Number of Months after Randomization.).Exercise capacity improved by more than 10 W in 28 percent, 22 percent, and 15 percent of patients in the surgery group after 6, 12, and 24 months, respectively, as compared with 4 percent, 5 percent, and 3 percent of patients in the medical-therapy group (P<0.001 for the comparisons at all three time points) (Table 3Table 3
Improvement in Exercise Capacity and Health-Related Quality of Life at 24 Months. and Supplementary Appendix 4 [available with the full text of this article at http://www.nejm.org]). Patients in the surgery group were significantly more likely to have improvements than patients in the medical-therapy group in the distance walked in six minutes, percentage of the predicted value for FEV1, general and health-related quality of life, and degree of dyspnea (see Supplementary Appendix 4).High-Risk Patients
The subgroup of 140 patients with a value for FEV1 that was 20 percent or less of the predicted value and either homogeneous emphysema or a carbon monoxide diffusing capacity that was 20 percent or less of the predicted value was previously reported to be at high risk for death after lung-volume–reduction surgery, with little chance of functional benefit.17 The updated analyses of mortality and functional improvement in this subgroup support the previous findings (Table 2 and Table 3 and Figure 1B).
Outcomes for Patients without High Risk
Among the 1078 patients who were not at high risk, the 30-day mortality rate was 2.2 percent in the surgery group, as compared with 0.2 percent in the medical-therapy group (P<0.001), and the 90-day mortality rate was 5.2 percent in the surgery group, as compared with 1.5 percent in the medical-therapy group (P=0.001) (Table 2). One month after randomization, 28.1 percent of the patients in the surgery group, as compared with 2.2 percent of the patients in the medical-therapy group, were hospitalized, living in a nursing or rehabilitation facility, or unavailable for interview but not known to be dead (P<0.001 for the comparison between groups); at two months, the percentages were 14.3 percent and 3.3 percent, respectively (P<0.001); at four months, 6.7 percent and 3.2 percent, respectively (P=0.007); and at eight months, 3.3 percent and 3.7 percent, respectively (P=0.87) (see Supplementary Appendix 5 [available with the full text of this article at http://www.nejm.org]).
Total mortality among patients who were not at high risk during the trial was 0.09 death per person-year in the surgery group, as compared with 0.10 death per person-year in the medical-therapy group (risk ratio, 0.89; P=0.31) (Table 2 and Figure 1C). Changes in exercise capacity, distance walked in six minutes, percentage of the predicted value for FEV1, quality of life, and degree of dyspnea at 6, 12, and 24 months all favored the surgery group (Table 3, Figure 2Figure 2
Histograms of Changes from Base Line in Exercise Capacity (Maximal Workload), Percentage of the Predicted Value for Forced Expiratory Volume in One Second (FEV1), and Quality of Life (Quality of Well-Being Score) after 6, 12, and 24 Months of Follow-up., and Supplementary Appendix 6 [available with the full text of this article at http://www.nejm.org]). When the analysis was limited to survivors who were able to complete the follow-up assessments, the pattern of changes in the outcome measures showed a progressive decline from base line in the medical-therapy group; the surgery group had improvements from base line but also had a gradual decline over the course of 24 months (see Supplementary Appendix 7 [available with the full text of this article at http://www.nejm.org]).Preoperative Predictors of Outcomes among Patients without High Risk
The only individual base-line factors associated with differences in mortality between the treatment groups were the craniocaudal distribution of emphysema (presence or absence of upper-lobe predominance, P for interaction = 0.02) and base-line exercise capacity (low or high, P for interaction = 0.01). The only individual base-line factor associated with differential improvement in the maximal workload at 24 months was the craniocaudal distribution of emphysema (presence or absence of upper-lobe predominance, P for interaction = 0.005). No base-line factor we considered was predictive of differential improvement in the health-related quality of life.
When patients were divided into four subgroups on the basis of combinations of upper-lobe or non–upper-lobe emphysema and low or high exercise capacity at base line, there was strong evidence of differential effects on the risk of death (P for interaction = 0.004) and on exercise capacity at 24 months (P for interaction = 0.005). Among 290 patients with upper-lobe disease and low exercise capacity, patients in the surgery group had a lower risk of death than patients in the medical-therapy group (risk ratio, 0.47; P=0.005) (Figure 1D and Table 2), were more likely to have an improvement of more than 10 W in the maximal workload at 24 months (30 percent vs. 0 percent, P<0.001) (Table 3), and were more likely to have an eight-point improvement in the St. George's Respiratory Questionnaire score at 24 months (48 percent vs. 10 percent, P<0.001) (Table 3).
Among the 419 patients with upper-lobe disease and high exercise capacity, mortality was similar, regardless of the treatment-group assignment (risk ratio for death in the surgery group, 0.98; P=0.70) (Figure 1E and Table 2). However, patients in the surgery group were more likely than those in the medical-therapy group to have improvement of more than 10 W in the maximal workload at 24 months (15 percent vs. 3 percent, P=0.001) (Table 3) and to have an eight-point improvement in the health-related quality-of-life score at 24 months (41 percent vs. 11 percent, P<0.001) (Table 3).
The 149 patients with non–upper-lobe disease and low exercise capacity had a similar risk of death, regardless of the treatment group (risk ratio for the surgery group, 0.81; P=0.49) (Figure 1F and Table 2), and had similar chances of improvement of more than 10 W in the maximal workload at 24 months, regardless of the treatment group (12 percent vs. 7 percent, P=0.50) (Table 3), but patients in the surgery group had a greater chance than patients in the medical-therapy group of an eight-point improvement in health-related quality of life at 24 months (37 percent vs. 7 percent, P=0.001) (Table 3).
Among the 220 patients with non–upper-lobe disease and high exercise capacity, patients in the surgery group had a higher risk of death than those in the medical-therapy group (risk ratio, 2.06; P=0.02) (Figure 1G and Table 2), a similarly low chance of improvement of more than 10 W in the maximal workload at 24 months (3 percent in both groups, P=1.00) (Table 3), and a similar chance of an eight-point improvement in health-related quality of life (15 percent vs. 12 percent, P=0.61) (Table 3).
Changes in the maximal workload are shown in Figure 3Figure 3
Histograms of Changes from Base Line in Exercise Capacity (Maximal Workload) after 6, 12, and 24 Months of Follow-up in Subgroups of Non–High-Risk Patients. for these four subgroups of patients. For patients with either predominantly upper-lobe emphysema or low exercise capacity after rehabilitation, outcomes favored the surgery group at nearly all time points. Similar patterns of outcomes were seen in the changes in the total daily score for health-related quality of life in these subgroups (see Supplementary Appendix 8 [available with the full text of this article at http://www.nejm.org]). Only in the subgroup with both non–upper-lobe emphysema and high maximal workload at base line did patients in the surgery group not have greater functional and symptomatic improvement than patients in the medical-therapy group.Discussion
Our study provides reliable estimates of risk and benefit from lung-volume–reduction surgery because of the size of the sample, the use of randomization, the participation of multiple institutions, the use of well-defined measurements, the long-term follow-up, and the low crossover rates. Overall mortality was similar in the surgery and medical-therapy groups, both for all patients and when the previously identified high-risk patients were excluded. Lung-volume–reduction surgery was associated with a greater chance of improvement in exercise capacity, lung function, quality of life, and dyspnea, but the changes after surgery were highly variable, both among all patients and among those who were not at high risk. After two years, values for the measures of function in survivors in the surgery group had returned nearly to base-line levels, on average, and the values in survivors in the medical-therapy group had continued to deteriorate to levels below base-line values. The functional benefits of lung-volume–reduction surgery came at the price of increased short-term mortality and morbidity.
Because of the broad criteria for inclusion in our study, analysis of prognostic factors allowed us to identify subgroups of patients for whom decisions about lung-volume–reduction surgery are fairly clear-cut. We recognize the pitfalls of subgroup analyses, but we believe that the heterogeneity of the patients and of the outcomes and the considered approach we used make our findings clinically and statistically valid. The subgroup-specific findings were not the result of data mining or the optimization of P values. The candidate prognostic factors we used to identify subgroups were in large part specified in advance on the basis of biologic rationale. The procedures and categorizations for identifying subgroups were carried out under the supervision of the independent data and safety monitoring board.
After high-risk patients had been excluded,17 four additional clinically meaningful subgroups of patients were identified on the basis of the pattern of emphysema on CT scanning and exercise capacity after rehabilitation. Patients with predominantly upper-lobe emphysema and a low maximal workload after rehabilitation had lower mortality, a greater probability of improvement in exercise capacity, and a greater probability of improvement in symptoms if they underwent lung-volume–reduction surgery than if they received medical therapy alone. In contrast, patients with predominantly non–upper-lobe emphysema and a high maximal workload after rehabilitation had higher mortality if they underwent lung-volume–reduction surgery than if they received medical therapy alone, and they had little chance of functional improvement regardless of the treatment they received. In these subgroups, the risks and benefits of surgery as compared with medical treatment are reasonably clear.
Mortality among the remaining patients was largely independent of the treatment-group assignment. For patients with predominantly upper-lobe disease and a high maximal workload, lung-volume–reduction surgery offered a greater chance for improvement in exercise capacity and symptoms than medical therapy, but only a small percentage of patients had an improvement in exercise capacity of more than 10 W from their base-line level. Patients with non–upper-lobe emphysema and a low maximal workload had only a small chance of improvement in exercise capacity, regardless of the treatment group, but had a greater chance of symptomatic improvement after lung-volume–reduction surgery than with medical therapy.
Upper-lobe emphysema has been associated with short-term improvement in pulmonary function after lung-volume–reduction surgery.25-27 Our study demonstrates that this pattern of disease is predictive of improved survival in patients who also have low maximal exercise capacity. Upper-lobe predominance, as compared with other patterns, may result in clearer target areas for surgical resection or more accessible areas for excision, or it may indicate that the remaining lung tissue is healthier.
Low exercise capacity was an unanticipated predictor of a survival benefit after lung-volume–reduction surgery. The better survival among patients with low exercise capacity who underwent surgery appears to be due to the very high mortality and marked progressive functional limitation of the patients with low exercise capacity in the medical-therapy group.
Overall, lung-volume–reduction surgery offered no survival benefit. According to our subgroup analysis, it is likely that patients with certain characteristics will have improved survival and function. The survival benefit was limited to patients with predominantly upper-lobe emphysema and a low base-line exercise capacity, but functional benefits were noted in patients with predominantly upper-lobe emphysema and a high base-line exercise capacity and in patients with non–upper-lobe emphysema and a low base-line exercise capacity. Individual outcomes vary widely, but our study provides reliable estimates of outcomes to guide physicians and patients in making decisions about treatment.
Supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services, and the Agency for Healthcare Research and Quality.
This article was published at www.nejm.org on May 20, 2003.
Source Information
The writing committee for the National Emphysema Treatment Trial (NETT) (Alfred Fishman, M.D., University of Pennsylvania, Philadelphia; Fernando Martinez, M.D., University of Michigan, Ann Arbor; Keith Naunheim, M.D., Saint Louis University, St. Louis; Steven Piantadosi, M.D., Ph.D., and Robert Wise, M.D., Johns Hopkins University, Baltimore; Andrew Ries, M.D., M.P.H., University of California, San Diego, La Jolla; Gail Weinmann, M.D., National Heart, Lung, and Blood Institute, Bethesda, Md.; and Douglas E. Wood, M.D., University of Washington, Seattle) takes responsibility for the content of this article.
Address reprint requests to Dr. Piantadosi at the NETT Coordinating Center, 615 N. Wolfe St., Rm. 5010, Baltimore, MD 21205.
The members of the National Emphysema Treatment Trial Research Group are listed in the Appendix.
Appendix
The members of the National Emphysema Treatment Trial Research Group were as follows: Office of the Chair of the Steering Committee, University of Pennsylvania, Philadelphia: A.P. Fishman, B.A. Bozzarello, A. Al-Amin. Clinical Centers: Baylor College of Medicine, Houston: M. Katz, C. Wheeler, E. Baker, P. Barnard, J. Carter, S. Chatziioannou, K. Conejo-Gonzales, J. Haddad, D. Hicks, N. Kleiman, M. Milburn-Barnes, C. Nguyen, M. Reardon, J. Reeves-Viets, S. Sax, A. Sharafkhaneh, C. Young, R. Espada, R. Butanda, K. Dubose, M. Ellisor, P. Fox, K. Hale, E. Hood, A. Jahn, S. Jhingran, K. King, C. Miller, I. Nizami, T. Officer, J. Ricketts, J. Rodarte, R. Teague, K. Williams; Brigham and Women's Hospital, Boston: J. Reilly, D. Sugarbaker, C. Fanning, S. Body, S. Duffy, V. Formanek, A. Fuhlbrigge, P. Hartigan, S. Hooper, A. Hunsaker, F. Jacobson, M. Moy, S. Peterson, R. Russell, D. Saunders, S. Swanson; Cedars–Sinai Medical Center, Los Angeles: R. McKenna, Z. Mohsenifar, C. Geaga, M. Biring, S. Clark, R. Frantz, P. Julien, M. Lewis, J. Minkoff-Rau, V. Yegyan, M. Joyner; Cleveland Clinic Foundation, Cleveland: M. DeCamp, J. Stoller, Y. Meli, J. Apostolakis, D. Atwell, J. Chapman, P. DeVilliers, R. Dweik, E. Kraenzler, R. Lann, N. Kurokawa, S. Marlow, K. McCarthy, P. McCreight, A. Mehta, M. Meziane, O. Minai, P. O'Donovan, M. Steiger, K. White, J. Maurer, C. Hearn, S. Lubell, R. Schilz, T. Durr; Columbia University, New York, and Long Island Jewish Medical Center, New Hyde Park, N.Y.: M. Ginsburg, B. Thomashow, P. Jellen, J. Austin, M. Bartels, Y. Berkman, P. Berkoski, F. Brogan, A. Chong, G. DeMercado, A. DiMango, B. Kachulis, A. Khan, B. Mets, M. O'Shea, G. Pearson, J. Pfeffer, L. Rossoff, S. Scharf, M. Shiau, P. Simonelli, K. Stavrolakes, D. Tsang, D. Vilotijevic, C. Yip, M. Mantinaos, M. McKeon; Duke University Medical Center, Durham, N.C.: N. MacIntyre, R.D. Davis, J. Howe, R.E. Coleman, R. Crouch, D. Greene, K. Grichnik, D. Harpole, A. Krichman, B. Lawlor, H. McAdams, J. Plankeel, S. Rinaldo-Gallo, J. Smith, M. Stafford-Smith, V. Tapson, M. Steele, J. Norten; Mayo Foundation, Rochester, Minn.: J. Utz, C. Deschamps, K. Mieras, M. Abel, M. Allen, D. Andrist, G. Aughenbaugh, S. Bendel, E. Edell, M. Edgar, B. Edwards, B. Elliot, J. Garrett, D. Gillespie, J. Gurney, B. Hammel, K. Hanson, L. Hanson, G. Harms, J. Hart, T. Hartman, R. Hyatt, E. Jensen, N. Jenson, S. Kalra, P. Karsell, D. Midthun, C. Mottram, S. Swensen, A.-M. Sykes, K. Taylor, N. Torres, R. Hubmayr, D. Miller, S. Bartling, K. Bradt; National Jewish Medical and Research Center, Denver: B. Make, M. Pomerantz, M. Gilmartin, J. Canterbury, M. Carlos, P. Dibbern, E. Fernandez, L. Geyman, C. Hudson, D. Lynch, J. Newell, R. Quaife, J. Propst, C. Raymond, J. Whalen-Price, K. Winner, M. Zamora, R. Cherniack; Ohio State University, Columbus: P. Diaz, P. Ross, T. Bees, H. Awad, J. Drake, C. Emery, M. Gerhardt, M. Kelsey, M. King, D. Rittinger, M. Rittinger; Saint Louis University, St. Louis: K. Naunheim, F. Alvarez, J. Osterloh, S. Borosh, W. Chamberlain, S. Frese, A. Hibbit, M.E. Kleinhenz, G. Ruppel, C. Stolar, J. Willey, C. Keller; Temple University, Philadelphia: G. Criner, S. Furukawa, A.M. Kuzma, R. Barnette, N. Brister, K. Carney, W. Chatila, F. Cordova, G. D'Alonzo, M. Keresztury, K. Kirsch, C. Kwak, K. Lautensack, M. Lorenzon, U. Martin, P. Rising, S. Schartel, J. Travaline, G. Vance, P. Boiselle, G. O'Brien; University of California, San Diego, San Diego: A. Ries, R. Kaplan, C. Ramirez, D. Frankville, P. Friedman, J. Harrell, J. Johnson, D. Kapelanski, D. Kupferberg, C. Larsen, T. Limberg, M. Magliocca, F.J. Papatheofanis, D. Sassi-Dambron, M. Weeks; University of Maryland at Baltimore, Baltimore, and Johns Hopkins Hospital, Baltimore: M. Krasna, H. Fessler, I. Moskowitz, T. Gilbert, J. Orens, S. Scharf, D. Shade, S. Siegelman, K. Silver, C. Weir, C. White; University of Michigan, Ann Arbor: F. Martinez, M. Iannettoni, C. Meldrum, W. Bria, K. Campbell, P. Christensen, K. Flaherty, S. Gay, P. Gill, P. Kazanjian, E. Kazerooni, V. Knieper, T. Ojo, L. Poole, L. Quint, P. Rysso, T. Sisson, M. True, B. Woodcock, L. Zaremba; University of Pennsylvania, Philadelphia: L. Kaiser, J. Hansen-Flaschen, M.L. Geraghty, A. Alavi, T. Alcorn, J. Aronchick, S. Aukberg, B. Benedict, S. Craemer, R. Daniele, J. Edelman, W. Gefter, L. Kotler-Klein, R. Kotloff, D. Lipson, W. Miller, Jr., R. O'Connell, S. Opelman, W. Russell, H. Sheaffer, R. Simcox, S. Snedeker, J. Stone-Wynne, G. Tino, P. Wahl, J. Walter, P. Ward, D. Zisman, J. Mendez, A. Wurster; University of Pittsburgh, Pittsburgh: F. Sciurba, J. Luketich, C. Witt, G. Ayres, M. Donahoe, C. Fuhrman, R. Hoffman, J. Lacomis, J. Sexton, W. Slivka, D. Strollo, E. Sullivan, T. Simon, C. Wrona, G. Bauldoff, M. Brown, E. George, R. Keenan, T. Kopp, L. Silfies; University of Washington, Seattle: J. Benditt, D. Wood, M. Snyder, K. Anable, N. Battaglia, L. Boitano, A. Bowdle, L. Chan, C. Chwalik, B. Culver, T. Gillespy, D. Godwin, J. Hoffman, A. Ibrahim, D. Lockhart, S. Marglin, K. Martay, P. McDowell, D. Oxorn, L. Roessler, M. Toshima, S. Golden.
Other participants included the following: Agency for Healthcare Research and Quality, Rockville, Md.: L. Bosco, Y.-P. Chiang, C. Clancy, H. Handelsman; Centers for Medicare and Medicaid Services, Baltimore: S. Sheingold, T. Carino, J. Chin, J. Farrell, K. McVearry, A. Norris, S. Shirey, C. Sikora; Coordinating Center, Johns Hopkins University, Baltimore: S. Piantadosi, J. Tonascia, P. Belt, K. Collins, B. Collison, J. Dodge, M. Donithan, V. Edmonds, J. Fuller, J. Harle, R. Jackson, H. Koppelman, S. Lee, C. Levine, H. Livingston, J. Meinert, J. Meyers, D. Nowakowski, K. Owens, S. Qi, M. Smith, B. Simon, P. Smith, A. Sternberg, M. Van Natta, L. Wilson, R. Wise; Cost-Effectiveness Subcommittee: R.M. Kaplan, J.S. Schwartz, Y-P. Chiang, M.C. Fahs, A.M. Fendrick, A.J. Moskowitz, D. Pathak, S. Ramsey, S. Sheingold, A.L. Shroyer, J. Wagner, R. Yusen; Cost-Effectiveness Data Center, Fred Hutchinson Cancer Research Center, Seattle: S. Ramsey, R. Etzioni, S. Sullivan, D. Wood, T. Schroeder, R. Smith, K. Berry, N. Myers; CT Scan Image Storage and Analysis Center, University of Iowa, Iowa City: E. Hoffman, J. Cook-Granroth, A. Delsing, J. Guo, G. McLennan, B. Mullan, C. Piker, J. Reinhardt, J. Sieren, W. Stanford; Data and Safety Monitoring Board: J.A. Waldhausen, G. Bernard, D. DeMets, M. Ferguson, E. Hoover, R. Levine, D. Mahler, A.J. McSweeny, J. Wiener-Kronish, O.D. Williams, M. Younes; Marketing Center, Temple University, Philadelphia: G. Criner, C. Soltoff; Project Office, National Heart, Lung, and Blood Institute, Bethesda, Md.: G. Weinmann, J. Deshler, D. Follmann, J. Kiley, M. Wu.
- References
References
1
Cooper JD ,Patterson GA ,Sundaresan RS , et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996;112:1319-1330
CrossRef | Web of Science | Medline2
Criner GJ ,Cordova FC ,Furukawa S , et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:2018-2027
Web of Science | Medline3
Flaherty KR ,Kazerooni EA ,Curtis JL , et al. Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 2001;119:1337-1346
CrossRef | Web of Science | Medline4
Geddes D ,Davies M ,Koyama H , et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med 2000;343:239-245
Full Text | Web of Science | Medline5
Sciurba FC ,Rogers RM ,Keenan RJ , et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996;334:1095-1099
Full Text | Web of Science | Medline6
Brenner M ,Yusen R ,McKenna R Jr , et al. Lung volume reduction surgery for emphysema. Chest 1996;110:205-218
CrossRef | Web of Science | Medline7
Gelb AF ,McKenna RJ Jr ,Brenner M ,Schein MJ ,Zamel N ,Fischel R . Lung function 4 years after lung volume reduction surgery for emphysema. Chest 1999;116:1608-1615
CrossRef | Web of Science | Medline8
Pompeo E ,Marino M ,Nofroni I ,Matteucci G ,Mineo TC . Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Ann Thorac Surg 2000;70:948-953
CrossRef | Web of Science | Medline9
Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg 1999;118:518-528
CrossRef | Web of Science | Medline10
American Thoracic Society
Web of Science | Medline11
American Thoracic Society
Web of Science | Medline12
Redelmeier DA ,Bayoumi AM ,Goldstein RS ,Guyatt GH . Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-1282
Web of Science | Medline13
Steele B . Timed walking tests of exercise capacity in chronic cardiopulmonary illness. J Cardiopulm Rehabil 1996;16:25-33
CrossRef | Medline14
Jones PW ,Quirk FH ,Baveystock CM ,Littlejohns P . A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327
Web of Science | Medline15
Kaplan RM ,Atkins CJ ,Timms R . Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984;37:85-95
CrossRef | Medline16
Eakin EG ,Resnikoff PM ,Prewitt LM ,Ries AL ,Kaplan RM . Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire: University of California, San Diego. Chest 1998;113:619-624
CrossRef | Web of Science | Medline17
National Emphysema Treatment Trial Research Group
Full Text | Web of Science | Medline18
Social Security Administration's Death Master File (full file). Springfield, Va.: National Technical Information Service, 2002. (NTIS order no. SUB-5251INQ.)
19
Social Security Administration Death Master monthly updates file. Springfield, Va.: National Technical Information Service, 2002. (NTIS order no. SUB-5446INQ.)
20
Jones PW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19:398-404
CrossRef | Web of Science | Medline21
Stata reference manual, version 7. College Station, Tex.: Stata Press, 2001.
22
Shih JH . Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials 1995;16:395-407
CrossRef | Medline23
Agresti A. An introduction to categorical data analysis. New York: John Wiley, 1996.
24
LogXact 4 for Windows: logistic regression software featuring exact methods. Cambridge, Mass.: Cytel Software, 2001.
25
Ingenito EP ,Loring SH ,Moy ML , et al. Comparison of physiological and radiological screening for lung volume reduction surgery. Am J Respir Crit Care Med 2001;163:1068-1073
Web of Science | Medline26
Wisser W ,Senbaklavaci O ,Ozpeker C , et al. Is long-term functional outcome after lung volume reduction surgery predictable? Eur J Cardiothorac Surg 2000;17:666-672
CrossRef | Web of Science | Medline27
Bloch KE ,Georgescu CL ,Russi EW ,Weder W . Gain and subsequent loss of lung function after lung volume reduction surgery in cases of severe emphysema with different morphologic patterns. J Thorac Cardiovasc Surg 2002;123:845-854
CrossRef | Web of Science | Medline
- Citing Articles (268)
Citing Articles
1
Sharon R. Rosenberg, Ravi Kalhan. (2012) Biomarkers in chronic obstructive pulmonary disease. Translational Research
CrossRef2
Robert M. Kaplan. (2012) Short, Simple, but Still of Uncertain Value. COPD: Journal of Chronic Obstructive Pulmonary Disease 9:1, 1-2
CrossRef3
Robert F. Browning, J. Francis Turner, Ko-Pen Wang. 2012. Indications and Contraindications in Flexible Bronchoscopy. , 70-91.
CrossRef4
Sherry L. Tidwell, Elizabeth Westfall, Mark T. Dransfield. (2012) Lung Volume Reduction for Advanced Emphysema. Southern Medical Journal 105:1, 56-61
CrossRef5
Masataka Irie, Ryoichi Nakanishi, Kazumi Hamada, Masamitsu Kido. (2011) Perioperative Short-term Pulmonary Rehabilitation for Patients Undergoing Lung Volume Reduction Surgery. COPD: Journal of Chronic Obstructive Pulmonary Disease 8:6, 444-449
CrossRef6
Hiren J. Mehta, Christopher Ross, Gerard A. Silvestri, Roy H. Decker. (2011) Evaluation and Treatment of High-Risk Patients with Early-Stage Lung Cancer. Clinics in Chest Medicine 32:4, 783-797
CrossRef7
Melissa Jehn, Arno Schmidt-Trucksäss, Anja Meyer, Christian Schindler, Michael Tamm, Daiana Stolz. (2011) Association of daily physical activity volume and intensity with COPD severity. Respiratory Medicine 105:12, 1846-1852
CrossRef8
Annemarie Relyea-Chew. (2011) Ethical Considerations in CMS's Coverage With Evidence Development. Journal of the American College of Radiology 8:12, 838-841
CrossRef9
M. H. Cho, P. J. Castaldi, E. S. Wan, M. Siedlinski, C. P. Hersh, D. L. Demeo, B. E. Himes, J. S. Sylvia, B. J. Klanderman, J. P. Ziniti, C. Lange, A. A. Litonjua, D. Sparrow, E. A. Regan, B. J. Make, J. E. Hokanson, T. Murray, J. B. Hetmanski, S. G. Pillai, X. Kong, W. H. Anderson, R. Tal-Singer, D. A. Lomas, H. O. Coxson, L. D. Edwards, W. MacNee, J. Vestbo, J. C. Yates, A. Agusti, P. M. A. Calverley, B. Celli, C. Crim, S. Rennard, E. Wouters, P. Bakke, A. Gulsvik, J. D. Crapo, T. H. Beaty, E. K. Silverman, . (2011) A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics
CrossRef10
Armin Ernst, Devanand Anantham. (2011) Update on Interventional Bronchoscopy for the Thoracic Radiologist. Journal of Thoracic Imaging 26:4, 263-277
CrossRef11
(2011) Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía-2010. SEMERGEN - Medicina de Familia 37:9, 468-495
CrossRef12
Ron Balkissoon, Steve Lommatzsch, Brendan Carolan, Barry Make. (2011) Chronic Obstructive Pulmonary Disease: A Concise Review. Medical Clinics of North America 95:6, 1125-1141
CrossRef13
Jean-Marc Delay, Samir Jaber. (2011) Préparation respiratoire préopératoire des patients insuffisants respiratoires chroniques. La Presse Médicale
CrossRef14
A. Delage, C.-H. Marquette. (2011) Bronchoscopic treatments for emphysema. Revue des Maladies Respiratoires
CrossRef15
Jaime Mata, Talissa Altes, Jonathon Truwit, Peter Sylvester, Eduard de Lange, Yun Shim, Ajeet Vinayak, James Brookeman, John Mugler. (2011) Characterization and Detection of Physiologic Lung Changes Before and After Placement of Bronchial Valves Using Hyperpolarized Helium-3 MR Imaging. Academic Radiology 18:9, 1195-1199
CrossRef16
PL Shah, D-J Slebos, PFG Cardoso, E Cetti, K Voelker, B Levine, ME Russell, J Goldin, M Brown, JD Cooper, GW Sybrecht. (2011) Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. The Lancet 378:9795, 997-1005
CrossRef17
Walter Weder, Erich W Russi. (2011) Lung-volume reduction by airway bypass. The Lancet 378:9795, 966-967
CrossRef18
Sheila Sivam, Frank C. Sciurba, Lorrie A. Lucht, Yingze Zhang, Steven R. Duncan, Karen A. Norris, Alison Morris. (2011) Distribution of Pneumocystis jirovecii in lungs from colonized COPD patients. Diagnostic Microbiology and Infectious Disease 71:1, 24-28
CrossRef19
Carolyn E. Come, Miguel J. Divo, Raúl San José Estépar, Frank C. Sciurba, Gerard J. Criner, Nathaniel Marchetti, Steven M. Scharf, Zab Mosenifar, Barry J. Make, Cesar A. Keller, Omar A. Minai, Fernando J. Martinez, MeiLan K. Han, John J. Reilly, Bartolome R. Celli, George R. Washko. (2011) Lung deflation and oxygen pulse in COPD: Results from the NETT randomized trial. Respiratory Medicine
CrossRef20
Peter J. Lipman, Michael H. Cho, Per Bakke, Amund Gulsvik, Xiangyang Kong, David A. Lomas, Wayne Anderson, Edwin K. Silverman, Christoph Lange. (2011) On the follow-up of genome-wide association studies: an overall test for the most promising SNPs. Genetic Epidemiology 35:5, 303-309
CrossRef21
O. Freynet, G. Jebrak, P.-R. Burgel. (2011) Bronchopneumopathie chronique obstructive. Revue des Maladies Respiratoires Actualités 3:6, 45-63
CrossRef22
Marc Estenne, Henry E. Fessler, Malcolm M. DeCamp. 2011. Lung Transplantation and Lung Volume Reduction Surgery. .
CrossRef23
G. Miranda, A. Gómez, E. Pleguezuelos, L. Capellas. (2011) Rehabilitación respiratoria en España. Encuesta SORECAR. Rehabilitación 45:3, 247-255
CrossRef24
Antonio Román, Pietat Ussetti, Amparo Solé, Felipe Zurbano, José M. Borro, José M. Vaquero, Alicia de Pablo, Pilar Morales, Marina Blanco, Carlos Bravo, José Cifrian, Mercedes de la Torre, Pablo Gámez, Rosalía Laporta, Víctor Monforte, Roberto Mons, Ángel Salvatierra, Francisco Santos, Joan Solé, Andrés Varela. (2011) Normativa para la selección de pacientes candidatos a trasplante pulmonar. Archivos de Bronconeumología 47:6, 303-309
CrossRef25
Robert H. Brown. (2011) Quantifying the Extent of Emphysema. Academic Radiology 18:6, 659-660
CrossRef26
Roger D. Yusen. (2011) Survival and Quality of Life of Patients Undergoing Lung Transplant. Clinics in Chest Medicine 32:2, 253-264
CrossRef27
Andrew R. Berman. (2011) Management of Patients with End-Stage Chronic Obstructive Pulmonary Disease. Primary Care: Clinics in Office Practice 38:2, 277-297
CrossRef28
Gerard J. Criner. (2011) Alternatives to Lung Transplantation: Lung Volume Reduction for COPD. Clinics in Chest Medicine 32:2, 379-397
CrossRef29
Jose M. Marin, Claudia G. Cote, Orlando Diaz, Carmen Lisboa, Ciro Casanova, Maria V. Lopez, Santiago J. Carrizo, Victor Pinto-Plata, Luis J. Dordelly, Hafida Nekach, Bartolome R. Celli. (2011) Prognostic assessment in COPD: Health related quality of life and the BODE index. Respiratory Medicine 105:6, 916-921
CrossRef30
Antonio Román, Pietat Ussetti, Amparo Solé, Felipe Zurbano, José M. Borro, José M. Vaquero, Alicia de Pablo, Pilar Morales, Marina Blanco, Carlos Bravo, José Cifrian, Mercedes de la Torre, Pablo Gámez, Rosalía Laporta, Víctor Monforte, Roberto Mons, Ángel Salvatierra, Francisco Santos, Joan Solé, Andrés Varela. (2011) Guidelines for the Selection of Lung Transplantation Candidates. Archivos de Bronconeumología (English Edition) 47:6, 303-309
CrossRef31
Claudio F. Donner, Johann Christian Virchow, Mirco Lusuardi. (2011) Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment. Respiratory Medicine 105:6, 828-837
CrossRef32
Samuel L. Krachman, Wissam Chatila, Ubaldo J. Martin, Irene Permut, Gilbert E. D'Alonzo, John P. Gaughan, Alice L Sternberg, David Ciccolella, Gerard J. Criner. (2011) Physiologic Correlates of Sleep Quality in Severe Emphysema. COPD: Journal of Chronic Obstructive Pulmonary Disease 8:3, 182-188
CrossRef33
Felix JF Herth, Ralf Eberhardt, Edward P Ingenito, Daniela Gompelmann. (2011) Assessment of a novel lung sealant for performing endoscopic volume reduction therapy in patients with advanced emphysema. Expert Review of Medical Devices 8:3, 307-312
CrossRef34
Edwin K. Silverman, Jørgen Vestbo, Alvar Agusti, Wayne Anderson, Per S. Bakke, Kathleen C. Barnes, R. Graham Barr, Eugene R. Bleecker, H. Marike Boezen, Kristin M. Burkart, Bartolome R. Celli, Michael H. Cho, William O.C. Cookson, Thomas Croxton, Denise Daley, Dawn L. DeMeo, Weiniu Gan, Judith Garcia-Aymerich, Ian P. Hall, Nadia N. Hansel, Craig P. Hersh, Noor Kalsheker, James P. Kiley, Woo Jin Kim, Diether Lambrechts, Sang-Do Lee, Augusto A. Litonjua, David A. Lomas, Stephanie J. London, Masaharu Nishimura, Borge G. Nørdestgaard, Christopher J. O'Donnell, Dirkje S. Postma, Milo A. Puhan, Yohannes Tesfaigzi, Martin D. Tobin, Claus Vogelmeier, Jemma B. Wilk, Emiel Wouters, Robert P. Young, Loems Ziegler-Heitbrock, William MacNee, James D. Crapo. (2011) Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. COPD: Journal of Chronic Obstructive Pulmonary Disease 8:2, 121-135
CrossRef35
Luis Seijo Maceiras. (2011) Luces y sombras del tratamiento endoscópico del enfisema. Archivos de Bronconeumología 47:4, 167-168
CrossRef36
Lorenzo Corbetta, Fabrizio Luppi, Raffaele A. Incalzi. (2011) Linee guida sulla BPCO non associata a comorbilità croniche. Italian Journal of Medicine 5:1, 14-21
CrossRef37
Francesco Sgambato, Enrico Clini. (2011) Complessità del paziente con insufficienza respiratoria cronica associata a BPCO. Italian Journal of Medicine 5:1, 159-170
CrossRef38
F. Giraud, S. Quétant. (2011) Endoscopie bronchique. Revue des Maladies Respiratoires Actualités 3:1, 34-39
CrossRef39
Roberto Benzo. (2011) Lung volume reduction surgery: nonpharmacological approach. Current Opinion in Anaesthesiology 24:1, 44-48
CrossRef40
(2011) Endobronchial Valves for Emphysema. New England Journal of Medicine 364:4, 381-384
Full Text41
Rokhsara Rafii, Timothy E. Albertson, Samuel Louie, Andrew L. Chan. (2011) Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease. Pulmonary Medicine 2011, 1-11
CrossRef42
M.Á. Santolaria López, P. Roche Roche, J. Costán Galicia, F.J. Suárez Pinilla, A. Pérez Trullén, L. Anoro Abenoza. (2011) Autobullectomía bilateral. Revista de Patología Respiratoria 14:1, 19-22
CrossRef43
Armin Ernst, Devanand Anantham. (2011) Bronchoscopic Lung Volume Reduction. Pulmonary Medicine 2011, 1-6
CrossRef44
Luis Seijo Maceiras. (2011) Pros and Cons of Endoscopic Treatment of Emphysema. Archivos de Bronconeumología (English Edition) 47:4, 167-168
CrossRef45
J. Votruba, J. Collins, F.J.F. Herth. (2011) Successful treatment of ventilator dependent emphysema with Chartis treatment planning and endobronchial valves. International Journal of Surgery Case Reports 2:8, 285-287
CrossRef46
Sakhee KOTECHA, Glen P WESTALL, Lynda HOLSWORTH, Alan PHAM, Trevor J WILLIAMS, Greg I SNELL. (2011) Long-term outcomes from bronchoscopic lung volume reduction using a bronchial prosthesis. Respirology 16:1, 167-173
CrossRef47
F.J.F. Herth, D. Gompelmann, F. Stanzel, R. Bonnet, J. Behr, B. Schmidt, H. Magnussen, A. Ernst, R. Eberhardt. (2011) Treatment of Advanced Emphysema with Emphysematous Lung Sealant (AeriSeal®). Respiration 82:1, 36-45
CrossRef48
Alan M. Garber, Mark J. Sculpher. 2011. Cost Effectiveness and Payment Policy. , 471-497.
CrossRef49
Silvia Park, Sang Moo Lee. (2011) Evidence-based healthcare and the need of conditional decision. Journal of the Korean Medical Association 54:12, 1319
CrossRef50
Jordan A Guenette, Dennis Jensen, Denis E OʼDonnell. (2010) Respiratory function and the obesity paradox. Current Opinion in Clinical Nutrition and Metabolic Care 13:6, 618-624
CrossRef51
Steven C. S. CHUNG, Matthew J. PETERS, Stephanie CHEN, Louise EMMETT, Alvin J. ING. (2010) Effect of unilateral endobronchial valve insertion on pulmonary ventilation and perfusion: A pilot study. Respirology 15:7, 1079-1083
CrossRef52
C. Daniel Mullins, Danielle Whicher, Emily S. Reese, Sean Tunis. (2010) Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials. PharmacoEconomics 28:10, 969-976
CrossRef53
Timothy J. Gardner. (2010) Are randomized trials the best way to judge the efficacy of surgical procedures?. The Journal of Thoracic and Cardiovascular Surgery 140:4, 739-742
CrossRef54
Paul SEXTON, Jeffrey E. GARRETT, Nigel RANKIN, Graeme ANDERSON. (2010) Endoscopic lung volume reduction effectively treats acute respiratory failure secondary to bullous emphysema. Respirology 15:7, 1141-1145
CrossRef55
Matthew Brown, Fereidoun Abtin, Hyun J Kim, Michael McNitt-Gray, Jonathan Goldin. (2010) Imaging biomarkers for patient selection and treatment planning in emphysema. Imaging in Medicine 2:5, 565-573
CrossRef56
Sciurba, Frank C., Ernst, Armin, Herth, Felix J.F., Strange, Charlie, Criner, Gerard J., Marquette, Charles H., Kovitz, Kevin L., Chiacchierini, Richard P., Goldin, Jonathan, McLennan, Geoffrey, . (2010) A Randomized Study of Endobronchial Valves for Advanced Emphysema. New England Journal of Medicine 363:13, 1233-1244
Full Text57
Anzueto, Antonio, . (2010) Endobronchial Valves to Reduce Lung Hyperinflation. New England Journal of Medicine 363:13, 1280-1281
Full Text58
Michael Boyd, Trudy Boyd, Edmundo Rubio. (2010) Endoscopic Lung Volume Reduction. Clinical Pulmonary Medicine 17:5, 203-209
CrossRef59
Pablo Gerardo Sanchez, John Charles Kucharczuk, Stacey Su, Larry Robert Kaiser, Joel David Cooper. (2010) National Emphysema Treatment Trial redux: Accentuating the positive. The Journal of Thoracic and Cardiovascular Surgery 140:3, 564-572
CrossRef60
Alastair J. Moore, Rosa Suades Soler, Edward J. Cetti, S. Amanda Sathyapala, Nicholas S. Hopkinson, Michael Roughton, John Moxham, Michael I. Polkey. (2010) Sniff nasal inspiratory pressure versus IC/TLC ratio as predictors of mortality in COPD. Respiratory Medicine 104:9, 1319-1325
CrossRef61
Cristine E. Berry, Robert A. Wise. (2010) Mortality in COPD: Causes, Risk Factors, and Prevention. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:5, 375-382
CrossRef62
Vickie R Shannon. (2010) Role of pulmonary rehabilitation in the management of patients with lung cancer. Current Opinion in Pulmonary Medicine 16:4, 334-339
CrossRef63
Daisuke Takenaka, Yoshiharu Ohno, Hisanobu Koyama, Munenobu Nogami, Yumiko Onishi, Keiko Matsumoto, Takeshi Yoshikawa, Sumiaki Matsumoto, Kazuro Sugimura. (2010) Co-registered perfusion SPECT/CT: Utility for prediction of improved postoperative outcome in lung volume reduction surgery candidates. European Journal of Radiology 74:3, 465-472
CrossRef64
O. Pato, P. Rama, M. Allegue, R. Fernández, D. González, J.M. Borro. (2010) Bronchoscopic Lung Volume Reduction in a Single-Lung Transplant Recipient With Natal Lung Hyperinflation: A Case Report. Transplantation Proceedings 42:5, 1979-1981
CrossRef65
Martijn A. Spruit, Michael L. Watkins, Lisa D. Edwards, Jørgen Vestbo, Peter M.A. Calverley, Victor Pinto-Plata, Bartolome R. Celli, Ruth Tal-Singer, Emiel F.M. Wouters. (2010) Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. Respiratory Medicine 104:6, 849-857
CrossRef66
Baskaran Sundaram, Aamer R. Chughtai, Ella A. Kazerooni. (2010) Multidetector High-resolution Computed Tomography of the Lungs. Journal of Thoracic Imaging 25:2, 125-141
CrossRef67
Niewoehner, Dennis E., . (2010) Outpatient Management of Severe COPD. New England Journal of Medicine 362:15, 1407-1416
Full Text68
Natalie H. Yip, George Yuen, Eliot J. Lazar, Brian K. Regan, Marcia D. Brinson, Brian Taylor, Liziamma George, Stephen R. Karbowitz, Richard Stumacher, Neil W. Schluger, Byron M. Thomashow. (2010) Analysis of Hospitalizations for COPD Exacerbation: Opportunities for Improving Care. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:2, 85-92
CrossRef69
M. Orozco-Levi, E. Marco Navarro, A.L. Ramírez-Sarmiento. (2010) Entrenamiento de los músculos respiratorios: ¿sí o no?. Rehabilitación 44:2, 167-176
CrossRef70
Victor Kim, Rita M. Pechulis, Mohammad Abuel-Haija, Charalambos C. Solomides, John P. Gaughan, Gerard J. Criner. (2010) Small Airway Pathology and Bronchoreversibility in Advanced Emphysema. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:2, 93-101
CrossRef71
Alastair J. Moore, Edward Cetti, Saleem Haj-Yahia, Martin Carby, Gunilla Björling, Sigbritt Karlsson, Pallav Shah, Peter Goldstraw, John Moxham, Simon Jordan, Michael I. Polkey. (2010) Unilateral Extrapulmonary Airway Bypass in Advanced Emphysema. The Annals of Thoracic Surgery 89:3, 899-906.e2
CrossRef72
Armin Ernst, Devanand Anantham. (2010) Endoscopic Management of Emphysema. Clinics in Chest Medicine 31:1, 117-126
CrossRef73
Matthew M. Puc, Seema S. Sonnad, Joseph B. Shrager. (2010) Early Outcomes After Bilateral Thoracoscopy Versus Median Sternotomy for Lung Volume Reduction. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 5:2, 97-102
CrossRef74
Michael H Cho, Nadia Boutaoui, Barbara J Klanderman, Jody S Sylvia, John P Ziniti, Craig P Hersh, Dawn L DeMeo, Gary M Hunninghake, Augusto A Litonjua, David Sparrow, Christoph Lange, Sungho Won, James R Murphy, Terri H Beaty, Elizabeth A Regan, Barry J Make, John E Hokanson, James D Crapo, Xiangyang Kong, Wayne H Anderson, Ruth Tal-Singer, David A Lomas, Per Bakke, Amund Gulsvik, Sreekumar G Pillai, Edwin K Silverman. (2010) Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nature Genetics 42:3, 200-202
CrossRef75
Anne E. Holland, Catherine J. Hill, Tshepo Rasekaba, Annemarie Lee, Matthew T. Naughton, Christine F. McDonald. (2010) Updating the Minimal Important Difference for Six-Minute Walk Distance in Patients With Chronic Obstructive Pulmonary Disease. Archives of Physical Medicine and Rehabilitation 91:2, 221-225
CrossRef76
Gregory W Fischer, Edmond Cohen. (2010) An update on anesthesia for thoracoscopic surgery. Current Opinion in Anaesthesiology 23:1, 7-11
CrossRef77
Peter J Mazzone. (2010) Preoperative evaluation of the lung cancer resection candidate. Expert Review of Respiratory Medicine 4:1, 97-113
CrossRef78
Lonny YARMUS, Armin ERNST, David FELLER-KOPMAN. (2010) Emerging technologies for the thorax: Indications, management and complications. Respirology 15:2, 208-219
CrossRef79
Penny E. Mohr, Sean R. Tunis. (2010) Access with Evidence Development. PharmacoEconomics 28:2, 153-162
CrossRef80
Tshering Amdo, Myrna C.B. Godoy, David Ost, David P. Naidich. (2010) Imaging–Bronchoscopic Correlations for Interventional Pulmonology. Thoracic Surgery Clinics 20:1, 103-119
CrossRef81
Craig P Hersh. (2010) Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 11:2, 237-247
CrossRef82
Alvar Agustí. (2010) Impacto de las nuevas opciones terapéuticas en la EPOC. Archivos de Bronconeumología 46, 1-2
CrossRef83
I. D. Pavord, A. J. Wardlaw. (2010) The A to E of airway disease. Clinical & Experimental Allergy 40:1, 62-67
CrossRef84
Jeremy A. Falk, Robert J. McKenna, Zab Mosenifar. 2010. Emphysema. , 147-154.
CrossRef85
Jong-Ha Lee, Chang-Hee Won, Nathaniel Marchetti. (2010) Determining the operative line of resection for image-guided emphysema surgery using a laser scanner and non-rigid registration. The International Journal of Medical Robotics and Computer Assisted Surgeryn/a-n/a
CrossRef86
Beatriz Amat, Günther Reichle, Carlos Agustí, Antoni Xaubet, Antoni Torres. (2010) What Is an Interventional Pulmonology Unit in Europe?. Clinical Pulmonary Medicine 17:1, 42-46
CrossRef87
Patricia Sobradillo, Judith García-Aymerich, Àlvar Agustí. (2010) Fenotipos clínicos de la EPOC. Archivos de Bronconeumología 46, 8-11
CrossRef88
S. Melanie Greaves, Kathleen Brown. 2010. Imaging of the Thoracic Surgery Patient. , 1-29.
CrossRef89
Heather D. Jones, Zab Mosenifar. 2010. Preoperative Assessment of High-Risk Patients for Lung Cancer Resection. , 288-292.
CrossRef90
Gregory I. Snell, Peter Hopkins, Glen Westall, Lynda Holsworth, Anne Carle, Trevor J. Williams. (2009) A Feasibility and Safety Study of Bronchoscopic Thermal Vapor Ablation: A Novel Emphysema Therapy. The Annals of Thoracic Surgery 88:6, 1993-1998
CrossRef91
H. Worth. (2009) Was ist gesichert in der Therapie der COPD?. Der Internist 50:12, 1345-1357
CrossRef92
H. Hoffmann, H. Dienemann. (2009) Entwicklung der Thoraxchirurgie in den nächsten 20 Jahren. Der Chirurg 80:12, 1121-1125
CrossRef93
Kosuke Kashiwabara, Ji-Ichiro Sasaki, Tsuyoshi Mori, Hiroaki Nomori, Kazuhiko Fujii, Hirotsugu Kohrogi. (2009) Relationship Between Functional Preservation after Segmentectomy and Volume-Reduction Effects after Lobectomy in Stage I Non-small Cell Lung Cancer Patients with Emphysema. Journal of Thoracic Oncology 4:9, 1111-1116
CrossRef94
Victor Kim, Robert M. Steiner. (2009) Interventional Treatment Options for Advanced Emphysema: Imaging Manifestations. Journal of Thoracic Imaging 24:3, 195-205
CrossRef95
Richard Beasley, Mark Weatherall, Justin Travers, Philippa Shirtcliffe. (2009) Time to define the disorders of the syndrome of COPD. The Lancet 374:9691, 670-672
CrossRef96
Silverman, Edwin K., Sandhaus, Robert A., . (2009) Alpha1-Antitrypsin Deficiency. New England Journal of Medicine 360:26, 2749-2757
Full Text97
Asad A Shah, Thomas A DʼAmico. (2009) Lung volume reduction surgery for the management of refractory dyspnea in chronic obstructive pulmonary disease. Current Opinion in Supportive and Palliative Care 3:2, 107-111
CrossRef98
Eric A. Hoffman, Rui Jiang, Heather Baumhauer, Michael A. Brooks, J. Jeffrey Carr, Robert Detrano, Joseph Reinhardt, Josanna Rodriguez, Karen Stukovsky, Nathan D. Wong, R. Graham Barr. (2009) Reproducibility and Validity of Lung Density Measures from Cardiac CT Scans—The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study1. Academic Radiology 16:6, 689-699
CrossRef99
Bas Groot Koerkamp, Y. Claire Wang, Myriam G.M. Hunink. (2009) Cost-effectiveness analysis for surgeons. Surgery 145:6, 616-622
CrossRef100
Cliff K. Choong, Balakrishnan Mahesh, G. Alexander Patterson, Joel D. Cooper. (2009) Concomitant Lung Cancer Resection and Lung Volume Reduction Surgery. Thoracic Surgery Clinics 19:2, 209-216
CrossRef101
James M. Donahue, Stephen D. Cassivi. (2009) Lung Volume Reduction Surgery for Patients with Alpha-1 Antitrypsin Deficiency Emphysema. Thoracic Surgery Clinics 19:2, 201-208
CrossRef102
Melanie A. Edwards, Stephen Hazelrigg, Keith S. Naunheim. (2009) The National Emphysema Treatment Trial: Summary and Update. Thoracic Surgery Clinics 19:2, 169-185
CrossRef103
Cliff K. Choong. (2009) Preface. Thoracic Surgery Clinics 19:2, xiii-xvi
CrossRef104
Steven C. Springmeyer, Chris T. Bolliger, Thomas K. Waddell, Xavier Gonzalez, Douglas E. Wood. (2009) Treatment of Heterogeneous Emphysema Using the Spiration IBV Valves. Thoracic Surgery Clinics 19:2, 247-253
CrossRef105
Samuel V. Kemp, Michael I. Polkey, Pallav L. Shah. (2009) The Epidemiology, Etiology, Clinical Features, and Natural History of Emphysema. Thoracic Surgery Clinics 19:2, 149-158
CrossRef106
Woo Jin Kim, Craig P. Hersh, Dawn L. DeMeo, John J. Reilly, Edwin K. Silverman. (2009) Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respiratory Medicine 103:4, 552-557
CrossRef107
Tshering Amdo, Myrna C.B. Godoy, David Ost, David P. Naidich. (2009) Imaging–Bronchoscopic Correlations for Interventional Pulmonology. Radiologic Clinics of North America 47:2, 271-287
CrossRef108
Christopher B. Cooper. (2009) Airflow obstruction and exercise. Respiratory Medicine 103:3, 325-334
CrossRef109
Alan Frederick Ross, J Scott Ferguson. (2009) Advances in interventional pulmonology. Current Opinion in Anaesthesiology 22:1, 11-17
CrossRef110
Peter Slinger. (2009) Update on anesthetic management for pneumonectomy. Current Opinion in Anaesthesiology 22:1, 31-37
CrossRef111
David K. Blough, Scott Ramsey, Sean D. Sullivan, Roger Yusen, . (2009) The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery. Health Economics 18:1, 91-101
CrossRef112
Walter Weder, Michaela Tutic, Didier Lardinois, Wolfgang Jungraithmayr, Sven Hillinger, Erich W. Russi, Konrad E. Bloch. (2009) Persistent Benefit From Lung Volume Reduction Surgery in Patients With Homogeneous Emphysema. The Annals of Thoracic Surgery 87:1, 229-237
CrossRef113
Saher Burhan Shaker, Trine Stavngaard, Marianne Hestad, Karen Skjoelstrup Bach, Philip Tonnesen, Asger Dirksen. (2009) The extent of emphysema in patients with COPD. The Clinical Respiratory Journal 3:1, 15-21
CrossRef114
Felipe Villar Álvarez, Germán Peces-Barba Romero. (2009) Marcadores pronósticos en la EPOC. Papel de la comorbilidad. Archivos de Bronconeumología 45, 2-7
CrossRef115
Stephen I. Rennard. 2009. Treatment for Stable COPD. , 823-836.
CrossRef116
Michael I. Polkey, Pallav L. Shah. 2009. Surgical and Other Mechanical Procedures. , 723-728.
CrossRef117
D.-E. O’Donnell. (2008) Implications cliniques de la distension thoracique, ou quand la physiopathologie change la prise en charge thérapeutique. Revue des Maladies Respiratoires 25:10, 1305-1318
CrossRef118
Neil A. Christie, Arjun Pennathur, Steven A. Burton, James D. Luketich. (2008) Stereotactic Radiosurgery for Early Stage Non-Small Cell Lung Cancer: Rationale, Patient Selection, Results, and Complications. Seminars in Thoracic and Cardiovascular Surgery 20:4, 290-297
CrossRef119
Marie-Pierre Revel, Jean-Baptiste Faivre, Martine Remy-Jardin, Valérie Deken, Alain Duhamel, Charles-Hugo Marquette, Nunzia Tacelli, Anne-Marie Bakai, Jacques Remy. (2008) Automated lobar quantification of emphysema in patients with severe COPD. European Radiology 18:12, 2723-2730
CrossRef120
Jeffrey J. Swigris, Kevin K. Brown, Barry J. Make, Frederick S. Wamboldt. (2008) Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Respiratory Medicine 102:12, 1675-1680
CrossRef121
Paul E. Wallner, Andre Konski. (2008) A Changing Paradigm in the Study and Adoption of Emerging Health Care Technologies: Coverage With Evidence Development. Journal of the American College of Radiology 5:11, 1125-1129
CrossRef122
P M A Calverley. (2008) COPD: what is the unmet need?. British Journal of Pharmacology 155:4, 487-493
CrossRef123
Patricia Macedo, Omar S. Usmani. (2008) Inhaled Drug Therapy in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 15:5, 239-247
CrossRef124
L. Zhao, X. J. Hu, S. W. Lagakos. (2008) Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach. Biostatistics 10:2, 310-323
CrossRef125
Carmen Paradis. (2008) Bias in Surgical Research. Annals of Surgery 248:2, 180-188
CrossRef126
Krisztina Czebe, Eszter Csiszér, György Lang, Peter Jaksch, Walter Klepetko. (2008) A tüdőtranszplantáció magyar történetének első 12 éve. Orvosi Hetilap 149:35, 1635-1644
CrossRef127
Edward Crosby. (2008) Innovation in medical practice: from new idea to standard of care. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 55:6, 328-336
CrossRef128
K. Robert Shen, John C. Wain, Cameron D. Wright, Hermes C. Grillo, Douglas J. Mathisen. (2008) Postpneumonectomy syndrome: Surgical management and long-term results. The Journal of Thoracic and Cardiovascular Surgery 135:6, 1210-1219.e6
CrossRef129
Mario Cazzola, Nicola A. Hanania, Paul W Jones, Donald A. Mahler, Barry Make, Jill Ohar, Stephen Rennard. (2008) It's about time – directing our attention toward modifying the course of COPD. Respiratory Medicine 102, S37-S48
CrossRef130
Bartolome R. Celli, Claudia G. Cote, Suzanne C. Lareau, Paula M. Meek. (2008) Predictors of Survival in COPD: More than Just the FEV1. Respiratory Medicine 102, S27-S35
CrossRef131
Scott D. Ramsey, David K. Blough, Sean D. Sullivan. (2008) A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach. Medical Care 46:5, 542-548
CrossRef132
Germán Peces-Barba, Joan Albert Barberà, Àlvar Agustí, Ciro Casanova, Alejandro Casas, José Luis Izquierdo, José Jardim, Victorina López Varela, Eduard Monsó, Teodoro Montemayor, José Luis Viejo. (2008) Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Archivos de Bronconeumología 44:5, 271-281
CrossRef133
Patricia Yerbury, Paul Bains, Vijay A. Selvan, Caroline Mooney, Christine Jones, Laura Blackler, Andrew Menzies-Gow. 2008. Symptom Management. , 27-64.
CrossRef134
William D.C. Man. 2008. Diagnosing COPD. , 13-26.
CrossRef135
T. Brett Reece, John D. Mitchell, Martin R. Zamora, David A. Fullerton, Joseph C. Cleveland, Marvin Pomerantz, Dennis M. Lyu, Frederick L. Grover, Michael J. Weyant. (2008) Native lung volume reduction surgery relieves functional graft compression after single-lung transplantation for chronic obstructive pulmonary disease. The Journal of Thoracic and Cardiovascular Surgery 135:4, 931-937
CrossRef136
Linda Nici. (2008) Preoperative and Postoperative Pulmonary Rehabilitation in Lung Cancer Patients. Thoracic Surgery Clinics 18:1, 39-43
CrossRef137
Richard F. Heitmiller, Jason M. Radecke, Christopher J. You. (2008) Resection of Apical Lung Tumors in High-Risk Patients Using Partial Sternotomy. The Annals of Thoracic Surgery 85:2, 678-680
CrossRef138
Coenraad F.N. Koegelenberg, Chris T. Bolliger. (2008) Assessing Regional Lung Function. Thoracic Surgery Clinics 18:1, 19-29
CrossRef139
William W. Merrill. (2008) From the Match to the Torch: New Progress Against an Old Adversary. The American Journal of the Medical Sciences 335:1, 2-6
CrossRef140
Thomas L Petty. (2008) Chronic Obstructive Pulmonary Disease. Disease Management & Health Outcomes 16:5, 273-274
CrossRef141
Fabrizio Luppi, Bianca Beghè, Lorenzo Corbetta, Leonardo M. Fabbri. 2008. Diagnosis of Asthma and COPD. , 523-541.
CrossRef142
Sandra D. Anderson, Jennifer A. Alison. 2008. Exercise as a Stimulus. , 495-506.
CrossRef143
Luis Javier Nannini, Christopher J Cates, Toby J Lasserson, Phillippa Poole, Luis Javier Nannini. 2007. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. .
CrossRef144
Luis Javier Nannini, Christopher J Cates, Toby J Lasserson, Phillippa Poole, Luis Javier Nannini. 2007. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. .
CrossRef145
Paulo F.G. Cardoso, Gregory I. Snell, Peter Hopkins, Gerhard W. Sybrecht, Georgios Stamatis, Alan W. Ng, Philip Eng. (2007) Clinical application of airway bypass with paclitaxel-eluting stents: Early results. The Journal of Thoracic and Cardiovascular Surgery 134:4, 974-981
CrossRef146
Christian A Merlo, Jonathan B Orens. (2007) Selection of candidates for lung transplantation. Current Opinion in Organ Transplantation 12:5, 479-484
CrossRef147
David J. Lederer, Selim M. Arcasoy. (2007) Update in Surgical Therapy for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, 639-653
CrossRef148
Claudia G. Cote, Bartolome R. Celli. (2007) Predictors of Mortality in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, 515-524
CrossRef149
Nicolino Ambrosino, Anita Simonds. (2007) The clinical management in extremely severe COPD. Respiratory Medicine 101:8, 1613-1624
CrossRef150
D. Bellamy, J. Smith. (2007) Role of primary care in early diagnosis and effective management of COPD. International Journal of Clinical Practice 61:8, 1380-1389
CrossRef151
I. Wan, T. Toma, D. Geddes, G. Snell, T. Williams, F. Venuta, A. Yim. (2007) Redução de volume pulmonar broncoscópico no enfisema em estádio terminal. Resultados dos primeiros 98 doentes. Revista Portuguesa de Pneumologia (English Edition) 13:4, 625-627
CrossRef152
David J. Lederer, Byron M. Thomashow, Mark E. Ginsburg, John H.M. Austin, Matthew N. Bartels, Chun K. Yip, Patricia A. Jellen, Frances L. Brogan, Steven M. Kawut, Roger A. Maxfield, Angela M. DiMango, Paul F. Simonelli, Lyall A. Gorenstein, Gregory D.N. Pearson, Joshua R. Sonett. (2007) Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. The Journal of Thoracic and Cardiovascular Surgery 133:6, 1434-1438
CrossRef153
Andrew C. Chang, Kevin M. Chan, Fernando J. Martinez. (2007) Lessons from the National Emphysema Treatment Trial. Seminars in Thoracic and Cardiovascular Surgery 19:2, 172-180
CrossRef154
Edward P. Ingenito, Larry W. Tsai. (2007) Evolving Endoscopic Approaches for Treatment of Emphysema. Seminars in Thoracic and Cardiovascular Surgery 19:2, 181-189
CrossRef155
P.-R. Burgel, N. Roche. (2007) Effet de la chirurgie de réduction de volume : l’index BODE a une valeur pronostique. Revue des Maladies Respiratoires 24, 51-52
CrossRef156
David J. Sugarbaker. (2007) Surgical Treatment of Emphysema: Introduction. Seminars in Thoracic and Cardiovascular Surgery 19:2, 133-134
CrossRef157
Steven J. Mentzer. (2007) Optimizing the Selection of Surgical Candidates for Lung Volume Reduction Surgery. Seminars in Thoracic and Cardiovascular Surgery 19:2, 151-156
CrossRef158
Jeffrey S. Sager, Robert M. Kotloff. (2007) Lung Transplantation for Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 14:3, 171-178
CrossRef159
Guillem Gómez Sebastián, Rosa Güell Rous, Araceli González Valencia, Juan José Fibla Alfara, Gaspar Estrada Saló, Carlos León González. (2007) Influencia de un programa de rescate en la decisión quirúrgica en pacientes con carcinoma broncogénico y EPOC. Archivos de Bronconeumología 43:5, 262-266
CrossRef160
A. Cortney Henderson, Edward P. Ingenito, Edgardo S. Salcedo, Marilyn L. Moy, John J. Reilly, Kenneth R. Lutchen. (2007) Dynamic lung mechanics in late-stage emphysema before and after lung volume reduction surgery. Respiratory Physiology & Neurobiology 155:3, 234-242
CrossRef161
Nagio Takigawa, Atsuhiko Tada, Ryo Soda, Hiroshi Date, Motohiro Yamashita, Shigeto Endo, Syuji Takahashi, Noriko Kawata, Takuo Shibayama, Noboru Hamada, Motoi Sakaguchi, Atsushi Hirano, Goro Kimura, Chiharu Okada, Kiyoshi Takahashi. (2007) Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. Respiratory Medicine 101:3, 561-567
CrossRef162
Néstor A Molfino. (2007) Current thinking on genetics of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 13:2, 107-113
CrossRef163
Nicholas S Hopkinson. (2007) Bronchoscopic lung volume reduction: indications, effects and prospects. Current Opinion in Pulmonary Medicine 13:2, 125-130
CrossRef164
Philip OʼReilly, William Bailey. (2007) Long-term continuous oxygen treatment in chronic obstructive pulmonary disease: proper use, benefits and unresolved issues. Current Opinion in Pulmonary Medicine 13:2, 120-124
CrossRef165
Calverley, Peter M.A., Anderson, Julie A., Celli, Bartolome, Ferguson, Gary T., Jenkins, Christine, Jones, Paul W., Yates, Julie C., Vestbo, Jørgen, . (2007) Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 356:8, 775-789
Full Text166
James K. Stoller, Thomas R. Gildea, Andrew L. Ries, Yvonne M. Meli, Matthew T. Karafa. (2007) Lung Volume Reduction Surgery in Patients With Emphysema and α-1 Antitrypsin Deficiency. The Annals of Thoracic Surgery 83:1, 241-251
CrossRef167
Adrian Gillissen, Hubertus Wirtz, Uwe Juergens. (2007) Patient and Physician Factors Contributing to Poor Outcomes in Patients with Asthma and COPD. Disease Management & Health Outcomes 15:6, 355-376
CrossRef168
Kate Fogg, Andrew McKee. 2007. Thoracic Surgery. , 188-204.
CrossRef169
Robert Sussman. (2007) Part I: Identifying chronic obstructive pulmonary disease in patients with respiratory symptoms. Current Medical Research and Opinion 23:s3, S5-S12
CrossRef170
Michael E. Friscia, Jianliang Zhu, Jeffrey W. Kolff, Zhen Chen, Larry R. Kaiser, Clifford S. Deutschman, Joseph B. Shrager. (2007) Cytokine Response is Lower After Lung Volume Reduction Through Bilateral Thoracoscopy Versus Sternotomy. The Annals of Thoracic Surgery 83:1, 252-256
CrossRef171
Marcus Dahlheim, Hermann Lindemann, Karl P. Paul, Nicolaus Schwerk. 2007. Atemwege. , 871-916.
CrossRef172
2007. C. , 39-51.
CrossRef173
Douglas E. Wood, Robert J. McKenna, Roger D. Yusen, Daniel H. Sterman, David E. Ost, Steven C. Springmeyer, H. Xavier Gonzalez, Michael S. Mulligan, Thomas Gildea, Ward V. Houck, Michael Machuzak, Atul C. Mehta. (2007) A multicenter trial of an intrabronchial valve for treatment of severe emphysema. The Journal of Thoracic and Cardiovascular Surgery 133:1, 65-73.e2
CrossRef174
Daniel H. Sterman. (2007) Biologic Lung Volume Reduction. Journal of Bronchology 14:1, 3-5
CrossRef175
S. Provencher, C. Poirier, V. Mainguy, M. Humbert, G. Simonneau. (2007) Il test del cammino per sei minuti in pneumologia. EMC - Medicina Riabilitativa 14:4, 1-6
CrossRef176
Laura Meinke, Rajinder Chitkara, Ganesh Krishna. (2007) Advances in the management of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 8:1, 23-37
CrossRef177
Yoko Goto, Masahiro Kohzuki, Makiko Meguro, Hajime Kurosawa. (2007) Long-Term Beneficial Effects of Lung Volume Reduction Surgery on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. The Tohoku Journal of Experimental Medicine 213:2, 157-166
CrossRef178
Luis Puente-Maestu, William W Stringer. (2006) Hyperinflation and its management in COPD. International Journal of COPD 1:4, 381-400
CrossRef179
Sebastien Gilbert, Bin Zheng, Joseph K. Leader, James D. Luketich, Carl R. Fuhrman, Rodney J. Landreneau, David Gur, Frank C. Sciurba. (2006) Computerized Estimation of the Lung Volume Removed During Lung Volume Reduction Surgery. Academic Radiology 13:11, 1379-1386
CrossRef180
H. Mal. (2006) Actualités thérapeutiques et BPCO. Revue des Maladies Respiratoires 23:5, 44-46
CrossRef181
Leong Ung Tiong, Peter G Gibson, Michael J Hensley, Rebecca Hepworth, Toby J Lasserson, Brian Smith, Huw Richard H R Davies, Leong Ung Tiong. 2006. Lung volume reduction surgery for diffuse emphysema. .
CrossRef182
2006. Chronic Obstructive Pulmonary Disease. .
CrossRef183
Tommaso Claudio Mineo, Eugenio Pompeo, Davide Mineo, Vincenzo Ambrogi, Donatella Ciarapica, Angela Polito. (2006) Resting Energy Expenditure and Metabolic Changes After Lung Volume Reduction Surgery for Emphysema. The Annals of Thoracic Surgery 82:4, 1205-1211
CrossRef184
A. Palou Rotger, E. Sala Llinàs. (2006) Enfermedad pulmonar obstructiva crónica (2). Medicine - Programa de Formación Médica Continuada Acreditado 9:63, 4080-4087
CrossRef185
Edward J. Cetti, Michael I. Polkey, Onn Min Kon, Pallav L. Shah, Duncan M. Geddes. (2006) Bronchoscopic Techniques for Treating Emphysema. Clinical Pulmonary Medicine 13:5, 263-270
CrossRef186
E. Q. Wu, H. G. Birnbaum, M. Cifaldi, Y. Kang, D. Mallet, G. Colice. (2006) Development of a COPD severity score. Current Medical Research and Opinion 22:9, 1679-1687
CrossRef187
Gerene S. Bauldoff, Philip T. Diaz. (2006) Improving Outcomes for COPD Patients. The Nurse Practitioner 31:8, 26???43
CrossRef188
Keith S. Naunheim, Douglas E. Wood, Zab Mohsenifar, Alice L. Sternberg, Gerard J. Criner, Malcolm M. DeCamp, Claude C. Deschamps, Fernando J. Martinez, Frank C. Sciurba, James Tonascia, Alfred P. Fishman. (2006) Long-Term Follow-Up of Patients Receiving Lung-Volume-Reduction Surgery Versus Medical Therapy for Severe Emphysema by the National Emphysema Treatment Trial Research Group. The Annals of Thoracic Surgery 82:2, 431-443.e19
CrossRef189
David M Mannino, Victor A Kiri. (2006) Changing the burden of COPD mortality. International Journal of COPD 1:3, 219-233
CrossRef190
Amgad El-Sherif, William E. Gooding, Ricardo Santos, Brian Pettiford, Peter F. Ferson, Hiran C. Fernando, Susan J. Urda, James D. Luketich, Rodney J. Landreneau. (2006) Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis. The Annals of Thoracic Surgery 82:2, 408-416
CrossRef191
Claude Lenfant. (2006) Will Lung Volume Reduction Surgery Be Widely Applied?. The Annals of Thoracic Surgery 82:2, 385-387
CrossRef192
Malcolm M. DeCamp, Eugene H. Blackstone, Keith S. Naunheim, Mark J. Krasna, Douglas E. Wood, Yvonne M. Meli, Robert J. McKenna. (2006) Patient and Surgical Factors Influencing Air Leak After Lung Volume Reduction Surgery: Lessons Learned From the National Emphysema Treatment Trial. The Annals of Thoracic Surgery 82:1, 197-207
CrossRef193
Edward P. Ingenito, Larry W. Tsai, Elizabeth Suki, Andrew Hoffman. (2006) Fibroblast Growth Factor-1 Therapy for Advanced Emphysema???A New Tissue Engineering Approach for Achieving Lung Volume Reduction. Journal of Bronchology 13:3, 114-123
CrossRef194
Jonathan B. Orens, Marc Estenne, Selim Arcasoy, John V. Conte, Paul Corris, Jim J. Egan, Thomas Egan, Shaf Keshavjee, Christiane Knoop, Robert Kotloff, Fernando J. Martinez, Steven Nathan, Scott Palmer, Alec Patterson, Lianne Singer, Gregory Snell, Sean Studer, J.L. Vachiery, Allan R. Glanville. (2006) International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update—A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. The Journal of Heart and Lung Transplantation 25:7, 745-755
CrossRef195
Michaela Tutic, Didier Lardinois, Stephan Imfeld, Stephan Korom, Annette Boehler, Rudolf Speich, Konrad E. Bloch, Erich W. Russi, Walter Weder. (2006) Lung-Volume Reduction Surgery as an Alternative or Bridging Procedure to Lung Transplantation. The Annals of Thoracic Surgery 82:1, 208-213
CrossRef196
Ruth Hardoff, David Shitrit, Ada Tamir, Adam P. Steinmetz, Yodphat Krausz, Mordchai R. Kramer. (2006) Short- and long-term outcome of lung volume reduction surgery. The predictive value of the preoperative clinical status and lung scintigraphy. Respiratory Medicine 100:6, 1041-1049
CrossRef197
(2006) Acetylcysteine in Pulmonary Fibrosis. New England Journal of Medicine 354:10, 1089-1091
Full Text198
K. Kenn. (2006) Rehabilitation und Trainingstherapie als Baustein der COPD-Therapie. Der Pneumologe 3:2, 110-118
CrossRef199
Matthew N. Bartels, Heakyung Kim, Jonathan H. Whiteson, Augusta S. Alba. (2006) Pulmonary Rehabilitation in Patients Undergoing Lung-Volume Reduction Surgery. Archives of Physical Medicine and Rehabilitation 87:3, 84-88
CrossRef200
N SCREATON, J REYNOLDS. (2006) Lung volume reduction surgery for emphysema: What the radiologist needs to know. Clinical Radiology 61:3, 237-249
CrossRef201
Carl Hugo Hamnegård, Michael I. Polkey, Anders Thylen, Folke Nilsson, Henrik Schersten, Björn Bake. (2006) Effect of lung volume reduction surgery for emphysema on diaphragm function. Respiratory Physiology & Neurobiology 150:2-3, 182-190
CrossRef202
Russell P. Bowler, Michael E. Canham, Misoo C. Ellison. (2006) Surface Enhanced Laser Desorption/Ionization (SELDI) Time-of-Flight Mass Spectrometry to Identify Patients with Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 3:1, 41-50
CrossRef203
Heiner Adams, Thomas Brack, Peter Kestenholz, Peter Vogt, Hans C. Steinert, Erich W. Russi. (2006) Diffuse Idiopathic Neuroendocrine Cell Hyperplasia Causing Severe Airway Obstruction in a Patient with a Carcinoid Tumor. Respiration 73:5, 690-693
CrossRef204
Li Zhang, E.A. Hoffman, J.M. Reinhardt. (2006) Atlas-driven lung lobe segmentation in volumetric X-ray CT images. IEEE Transactions on Medical Imaging 25:1, 1-16
CrossRef205
Edward P. Ingenito, Larry W. Tsai. 2006. Bronchoscopic Lung Volume Reduction. , 188-197.
CrossRef206
Jaume Sauleda Roig. (2006) Tratamiento endoscópico del enfisema. Archivos de Bronconeumología 42, 32-37
CrossRef207
Thomas L Petty. (2006) The history of COPD. International Journal of COPD 1:1, 3-14
CrossRef208
John D. Miller, Richard A. Malthaner, Charles H. Goldsmith, Ronald Goeree, David Higgins, P. Gerard Cox, Lawrence Tan, Jeremy D. Road. (2006) A Randomized Clinical Trial of Lung Volume Reduction Surgery Versus Best Medical Care for Patients With Advanced Emphysema: A Two-Year Study From Canada. The Annals of Thoracic Surgery 81:1, 314-321
CrossRef209
Michael S. Machuzak, David A. Lipson. (2006) Surgical Options in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 13:1, 1-7
CrossRef210
Tommaso Claudio Mineo, Eugenio Pompeo, Davide Mineo, Frederico Tacconi, Mario Marino, Alessandro Fabrizio Sabato. (2006) Awake Nonresectional Lung Volume Reduction Surgery. Annals of Surgery 243:1, 131-136
CrossRef211
Keith S. Naunheim, Douglas E. Wood, Mark J. Krasna, Malcolm M. DeCamp, Mark E. Ginsburg, Robert J. McKenna, Gerard J. Criner, Eric A. Hoffman, Alice L. Sternberg, Claude Deschamps. (2006) Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. The Journal of Thoracic and Cardiovascular Surgery 131:1, 43-53
CrossRef212
Yeon-Mok Oh. (2006) Bronchoscopic Lung Volume Reduction. Tuberculosis and Respiratory Diseases 61:6, 521
CrossRef213
Trine Stavngaard, Saher B. Shaker, Asger Dirksen. (2006) Quantitative assessment of emphysema distribution in smokers and patients with α1-antitrypsin deficiency. Respiratory Medicine 100:1, 94-100
CrossRef214
Bartolome Celli, Roger Goldstein, José Jardim, Katharine Knobil. (2005) Future perspectives in COPD. Respiratory Medicine 99, S41-S48
CrossRef215
Jane Reardon, Richard Casaburi, Michael Morgan, Linda Nici, Carolyn Rochester. (2005) Pulmonary rehabilitation for COPD. Respiratory Medicine 99, S19-S27
CrossRef216
Nicola A. Hanania, Nicolino Ambrosino, Peter Calverley, Mario Cazzola, Claudio F Donner, Barry Make. (2005) Treatments for COPD. Respiratory Medicine 99, S28-S40
CrossRef217
P VAUGHAN. (2005) Surgical treatment of pulmonary emphysema. Surgery (Oxford) 23:12, 435-438
CrossRef218
J. García de Tena, L. Manzano, M. Álvarez-Mon. (2005) Diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Medicine - Programa de Formación Médica Continuada Acreditado 9:46, 3022-3031
CrossRef219
Harvey O. Coxson, Robert M. Rogers. (2005) Quantitative Computed Tomography of Chronic Obstructive Pulmonary Disease1. Academic Radiology 12:11, 1457-1463
CrossRef220
Mark S. Conradi, Dmitriy A. Yablonskiy, Jason C. Woods, David S. Gierada, Richard E. Jacob, Yulin V. Chang, Cliff K. Choong, Alex L. Sukstanskii, Tariq Tanoli, Stephen S. Lefrak, Joel D. Cooper. (2005) 3He Diffusion MRI of the Lung1. Academic Radiology 12:11, 1406-1413
CrossRef221
G. Juan, M. Ramón, A. Cantó. (2005) Respuesta de los autores. Archivos de Bronconeumología 41:9, 535
CrossRef222
Dongfang Wang, Scott D. Lick, Kelly M. Campbell, David B. Loran, Scott K. Alpard, Joseph B. Zwischenberger, Sean D. Chambers. (2005) Development of Ambulatory Arterio-Venous Carbon Dioxide Removal (AVCO2R): The Downsized Gas Exchanger Prototype for Ambulation Removes Enough CO2 with Low Blood Resistance. ASAIO Journal 51:4, 385-389
CrossRef223
J.M. Marín, J.E. Alonso. (2005) El archivo de Archivos: 2004. Archivos de Bronconeumología 41:6, 341-348
CrossRef224
James K Stoller, Loutfi S Aboussouan. (2005) α1-antitrypsin deficiency. The Lancet 365:9478, 2225-2236
CrossRef225
Michaela Moonen, Jiahua Xu, Ake Johansson, Anders Thylen, Bjorn Bake. (2005) Effects of lung volume reduction surgery on distribution of ventilation and perfusion. Clinical Physiology and Functional Imaging 25:3, 152-157
CrossRef226
Steven J. Mentzer. (2005) Surgical Palliative Care in Thoracic Diseases. Surgical Clinics of North America 85:2, 315-328
CrossRef227
Basia Belza, Bonnie G. Steele, Kevin Cain, Jeff Coppersmith, JoEllen Howard, Sambasiva Lakshminarayan. (2005) Seattle Obstructive Lung Disease Questionnaire. Journal of Cardiopulmonary Rehabilitation 25:2, 107-114
CrossRef228
Margaret Nield, Guy Soo Hoo, Janice Roper, Silverio Santiago, Kathleen Dracup. (2005) Usefulness of the Human Activity Profile, a Functional Performance Measure, in People With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation 25:2, 115-121
CrossRef229
H. R. Wirtz. (2005) Chronische Bronchitis, COPD. Der Internist 46:2, 175-194
CrossRef230
Federico Venuta, Tiziano de Giacomo, Erino A. Rendina, Anna Maria Ciccone, Daniele Diso, Alessandro Perrone, Daniela Parola, Marco Anile, Giorgio F. Coloni. (2005) Bronchoscopic Lung-Volume Reduction With One-Way Valves in Patients With Heterogenous Emphysema. The Annals of Thoracic Surgery 79:2, 411-416
CrossRef231
Joel D Cooper. (2005) Lung Volume Reduction Surgery. Treatments in Respiratory Medicine 4:3, 211-213
CrossRef232
F. García Río. (2005) Importancia del atrapamiento aéreo en la EPOC. Archivos de Bronconeumología 41, 1-8
CrossRef233
Robert L Berger, Kathryn A Wood, Howard J Cabral, Sheila Goodnight-White, Edward P Ingenito, Anthony Gray, John Miller, Steven C Springmeyer. (2005) Lung Volume Reduction Surgery. Treatments in Respiratory Medicine 4:3, 201-209
CrossRef234
Rajeev SONI, Zoe J MCKEOUGH, Catherine J DOBBIN, Iven H YOUNG. (2005) Gas exchange and exercise tolerance following bullectomy. Respirology 10:1, 120-123
CrossRef235
James E. Hillier, Tudor P. Toma, Charles E. Gillbe. (2004) Bronchoscopic Lung Volume Reduction in Patients with Severe Emphysema: Anesthetic Management. Anesthesia & Analgesia1610-1614
CrossRef236
Akinori Iwasaki, Yasuteru Yoshinaga, Takayuki Shirakusa. (2004) Successful Removal of Bovine Pericardium by Bronchoscope After Lung Volume Reduction Surgery. The Annals of Thoracic Surgery 78:6, 2156-2157
CrossRef237
M. Pfeifer. (2004) Neue Therapiekonzepte bei COPD. Der Internist 45:12, 1395-1401
CrossRef238
Arieh Eden. (2004) Cost-Effectiveness of Lung-Volume-Reduction Surgery for Patients With Severe Emphysema. Survey of Anesthesiology 48:5, 228-229
CrossRef239
EFM Wouters. (2004) Management of severe COPD. The Lancet 364:9437, 883-895
CrossRef240
Michaela Tutic, Konrad E. Bloch, Didier Lardinois, Thomas Brack, Erich W. Russi, Walter Weder. (2004) Long-term results after lung volume reduction surgery in patients with α1-antitrypsin deficiency. The Journal of Thoracic and Cardiovascular Surgery 128:3, 408-413
CrossRef241
Yoko GOTO, Hajime KUROSAWA, Nobuyoshi MORI, Yoshimochi KUROKAWA, Wataru HIDA, Masahiro KOHZUKI. (2004) Improved activities of daily living, psychological state and health-related quality of life for 12 months following lung volume reduction surgery in patients with severe emphysema. Respirology 9:3, 337-344
CrossRef242
Thomas V Bilfinger. (2004) Surgical aspects in the treatment of lung cancer. Current Opinion in Pulmonary Medicine 10:4, 261-265
CrossRef243
Sutherland, E. Rand, Cherniack, Reuben M., . (2004) Management of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 350:26, 2689-2697
Full Text244
Hogg, James C., Chu, Fanny, Utokaparch, Soraya, Woods, Ryan, Elliott, W. Mark, Buzatu, Liliana, Cherniack, Ruben M., Rogers, Robert M., Sciurba, Frank C., Coxson, Harvey O., Paré, Peter D., . (2004) The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 350:26, 2645-2653
Full Text245
Anthony P.C Yim, Thomas M.T Hwong, Tak Wai Lee, Wilson W.L Li, Shirley Lam, Tai Kong Yeung, David S.C Hui, Fanny W.S Ko, Alan D.L Sihoe, Kin Hoi Thung, Ahmed A Arifi. (2004) Early results of endoscopic lung volume reduction for emphysema. The Journal of Thoracic and Cardiovascular Surgery 127:6, 1564-1573
CrossRef246
Gillick, Muriel R., . (2004) Medicare Coverage for Technological Innovations — Time for New Criteria?. New England Journal of Medicine 350:21, 2199-2203
Full Text247
Neil R. MacIntyre. (2004) Chronic Obstructive Pulmonary Disease. Pharmacotherapy 24:5 Part 2, 33S-43S
CrossRef248
(2004) Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. The Journal of Thoracic and Cardiovascular Surgery 127:5, 1350-1360
CrossRef249
Larry Tsai, Andrew Hoffman, Robert Berger, Edward Ingenito. (2004) Bronchoscopic Lung Volume Reduction in a Sheep Model of Heterogeneous Emphysema. Journal of Bronchology 11:2, 83-86
CrossRef250
Ganesh Krishna, Viji Sankaranarayanan, Rajinder K Chitkara. (2004) New therapies for chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs 13:3, 255-267
CrossRef251
Keith S Naunheim. (2004) Criteria for lung volume reduction surgery reimbursement: too many questions, not enough answers. The Journal of Thoracic and Cardiovascular Surgery 127:3, 631-632
CrossRef252
Terence K Trow. (2004) Lung-volume reduction surgery for severe emphysema. Current Opinion in Pulmonary Medicine 10:2, 128-132
CrossRef253
Keith S Naunheim. (2004) Update on lung volume reduction. Journal of Surgical Research 117:1, 134-143
CrossRef254
Linus H. Santo Tomas, Basil Varkey. (2004) Improving health-related quality of life in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 10:2, 120-127
CrossRef255
Bruno Degano, Laurent Brouchet, Jacques Rami, Jean-François Arnal, Roger Escamilla, Christophe Hermant, Marcel Dahan. (2004) Improvement after lung volume reduction surgery: a role for inspiratory muscle adaptation. Respiratory Physiology & Neurobiology 139:3, 293-301
CrossRef256
Konrad E. Bloch, Walter Weder, Lucas M. Bachmann, Erich W. Russi. (2004) Model-Based versus Clinical Prediction of the Spirometric Response to Lung Volume Reduction Surgery. Respiration 71:6, 611-618
CrossRef257
Vibha Bhatnagar, Susan T. Stewart, William W. Bonney, Robert M. Kaplan. (2004) Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. Urology 63:1, 103-109
CrossRef258
J. Hillier, C. Gillbe. (2003) Anaesthesia for lung volume reduction surgery. Anaesthesia 58:12, 1210-1219
CrossRef259
P CALVERLEY. (2003) What's new in & Asthma and COPD. Medicine 31:12, 1-3
CrossRef260
Anna Reed, Trevor Williams, Gregory Snell. (2003) Economic considerations and future directions for lung volume reduction surgery. Expert Review of Pharmacoeconomics & Outcomes Research 3:6, 729-740
CrossRef261
M MUERS. (2003) What's new in & Respiratory disorders. Medicine 31:11, 1-4
CrossRef262
Gregory Crosby. (2003) Neuroanesthesia Practice Standards: We Need Data, Not Dogma. Journal of Neurosurgical Anesthesiology 15:4, 337-340
CrossRef263
Eric A Hoffman, Joseph M Reinhardt, Milan Sonka, Brett A Simon, Junfeng Guo, Osama Saba, Deokiee Chon, Shaher Samrah, Hidenori Shikata, Juerg Tschirren, Kalman Palagyi, Kenneth C Beck, Geoffrey McLennan. (2003) Characterization of the interstitial lung diseases via density-based and texture-based analysis of computed tomography images of lung structure and function1. Academic Radiology 10:10, 1104-1118
CrossRef264
(2003) Lung-Volume–Reduction Surgery. New England Journal of Medicine 349:10, 999-1000
Full Text265
PMA Calverley, Paul Walker. (2003) Chronic obstructive pulmonary disease. The Lancet 362:9389, 1053-1061
CrossRef266
Ware, James H., . (2003) The National Emphysema Treatment Trial — How Strong Is the Evidence?. New England Journal of Medicine 348:21, 2055-2056
Full Text267
National Emphysema Treatment Trial Research Group. (2003) Cost Effectiveness of Lung-Volume–Reduction Surgery for Patients with Severe Emphysema. New England Journal of Medicine 348:21, 2092-2102
Full Text268
Drazen, Jeffrey M., Epstein, Arnold M., . (2003) Guidance Concerning Surgery for Emphysema. New England Journal of Medicine 348:21, 2134-2136
Full Text
- Letters
